The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin

European Journal of Cancer

Volumn 37, Issue 7, 2001, Pages 930-938

  Servidei, T ^a   Ferlini, C ^a   Riccardi, A ^a   Meco, D ^a   Scambia, G ^a   Segni, G ^a   Manzotti, C ^b   Riccardi, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NOVUSPHARMA   (Italy)

Author keywords

Apoptosis; BBR3464; Cell cycle; Cisplatin; Cisplatin resistance; p21; p53

Indexed keywords

BBR 3464; CISPLATIN; DNA; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL; CELL CYCLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DOSE RESPONSE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEUROBLASTOMA; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RHO GTP-BINDING PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035050647     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00061-2     Document Type: Article

References (32)

1. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts
2. Pattern of cellular sensitivity to BBR3464, a novel trinuclear platinum complex, in human tumour cell lines: Lack of cross-resistance with cisplatin
3. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system
4. The cellular basis of the efficacy of the trinuclear platinum complex BBR3464 against cisplatin-resistant cells
5. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent
6. Clinical implications of the p53 tumor-suppressor gene
7. A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumours
8. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2
9. Cellular response to cisplatin
10. 2 phase and cell death induced by cisplatin
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
12. Thymocyte apoptosis induced by p53-dependent and independent pathways
13. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
14. p53 in growth control and neoplasia
15. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis
16. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of ligands on molecular targets involved in proliferation
17. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis
18. Induction of differentiation in human promyelocytic HL-60 leukaemia cells activates p21, WAF1/CIP1, expression in the absence of p53
19. Induction of p21 (WAF-1/CIP1) during differentiation
20. Induction of WAF1/CIP1 by a p53-independent pathway
21. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity
22. Apoptosis, p53, and tumour cell sensitivity to anticancer agents
23. Cell death beyond apoptosis
24. Apoptosis and drug response
25. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
26. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants
27. BBR3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin
28. Structure and function of the p53 tumour suppressor gene: Clues for rational cancer therapeutic strategies
29. Characterisation of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
30. p53, the cellular gatekeeper for growth and division
31. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line
32. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis